Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 248

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 7
Chunk 248
---
 Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined
         under Section 13(d) of the Exchange Act) of the securities reported herein that are held by Intracoastal. The warrant is subject to a    
         beneficial ownership limitation of 4.99%, which such limitation restricts the shareholder from exercising that portion of the warrant    
        that would result in the shareholder and its affiliates owning, after exercise, a number of shares in excess of the beneficial ownership  
                          limitation. The principal business office of Intracoastal is 245 Palm Trail, Delray Beach, FL 33483.                    
--------------------------------------------------------------------------------------------------------------------------------------------------

(3)                           Includes 3,705,000 ordinary shares and 2,366,400 ordinary shares issuable upon exercise                         
      of outstanding options currently exercisable or exercisable within 60 days of March 26, 2025. Does not include 1,937,400 ordinary shares
                      issuable upon exercise of outstanding options that are not exercisable within 60 days of March 26, 2025.                
----------------------------------------------------------------------------------------------------------------------------------------------

(4)                     Includes 2,366,400 ordinary shares issuable upon exercise of outstanding options currently exercisable                 
      or exercisable within 60 days of March 26, 2025. Does not include 1,937,400 ordinary shares issuable upon exercise of outstanding options
                                              that are not exercisable within 60 days of March 26, 2025.                                       
-----------------------------------------------------------------------------------------------------------------------------------------------

(5)                             Includes 1,917,600 ordinary shares issuable upon exercise of outstanding options currently                         
      exercisable or exercisable within 60 days of March 26, 2025. Does not include 1,937,400 ordinary shares issuable upon exercise of outstanding
                                            options that are not exercisable within 60 days of March 26, 2025.                                     
---------------------------------------------------------------------------------------------------------------------------------------------------

(6)                                        Includes 2,366,400 ordinary shares issuable upon exercise of                                    
      outstanding options currently exercisable or exercisable within 60 days of March 26, 2025. Does not include 1,937,400 ordinary shares
                     issuable upon exercise of outstanding options that are not exercisable within 60 days of March 26, 2025.              
-------------------------------------------------------------------------------------------------------------------------------------------

(7)                                                         Includes 2,366,400 ordinary                                                       
          shares issuable upon exercise of outstanding options currently exercisable or exercisable within 60 days of